New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control
NCT ID NCT06531941
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of an experimental drug called MBX 2109 for people with hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. About 60 adults who finished a 12-week phase 2 study will receive weekly injections of MBX 2109 for an extended period. The main goal is to track any side effects and see if the drug remains safe over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MBX 2109 (a once-weekly injection)
- What this could lead to
- If successful, this could point toward a long-term treatment option for hypoparathyroidism that is safe and well-tolerated.
- What could go wrong
- This is a small, early-phase extension study focused on safety, not effectiveness. It may not show clear benefit, and side effects could emerge with longer use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MBX Biosciences Investigational Site
Miami, Florida, 33033, United States
-
MBX Biosciences Investigational Site
Macon, Georgia, 31210, United States
-
MBX Biosciences Investigational Site
Jackson, Mississippi, 39202, United States
-
MBX Biosciences Investigational Site
St Louis, Missouri, 63110, United States
-
MBX Biosciences Investigational Site
Las Vegas, Nevada, 89148, United States
-
MBX Biosciences Investigational Site
Reno, Nevada, 89511, United States
-
MBX Biosciences Investigational Site
Albany, New York, 12203, United States
-
MBX Biosciences Investigational Site
New York, New York, 10032, United States
-
MBX Biosciences Investigational Site
The Bronx, New York, 10467, United States
-
MBX Biosciences Investigational Site
Columbus, Ohio, 43201, United States
-
MBX Biosciences Investigational Site
Dallas, Texas, 75208, United States
-
MBX Biosciences Investigational Site
El Paso, Texas, 79935, United States
-
MBX Biosciences Investigational Site
Fort Worth, Texas, 76132, United States
-
MBX Biosciences Investigational Site
Round Rock, Texas, 78681, United States
-
MBX Biosciences Investigational Site
San Antonio, Texas, 78231, United States
-
MBX Biosciences Investigational Site
Weslaco, Texas, 78596, United States
-
MBX Biosciences Investigational Site
Madison, Wisconsin, 53705, United States
-
MBX Biosciences Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1012AAR, Argentina
-
MBX Biosciences Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425AGC, Argentina
-
MBX Biosciences Investigational Site
Córdoba, Río Cuarto, X5800AEV, Argentina
-
MBX Biosciences Investigational Site
Córdoba, X5000AAW, Argentina
-
MBX Biosciences Investigational Site
San Miguel de Tucumán, T4000IEH, Argentina
-
MBX Biosciences Investigational Site
Samsun, 55270, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder